ABSTRACT

Introduction

Although new drug classes have significantly extended survival of patients with multiple myeloma, they continue to experience multiple relapses and/or become refractory to treatment. Therefore, novel therapies and treatment combinations with different mechanisms of action are needed to improve the outcomes of patients with relapsed/refractory multiple myeloma.

Areas covered

Here, the authors review the published data regarding the development and clinical investigation of isatuximab, a CD38 monoclonal antibody, for treatment of patients with relapsed/refractory multiple myeloma. The mechanisms of action, clinical efficacy, and safety of isatuximab treatment are summarized.

Expert opinion

Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab displays a manageable safety profile, with infusion reactions being the most common adverse events. Isatuximab is currently being further evaluated in combination with other backbone regimens in relapsed/refractory and newly diagnosed multiple myeloma.

中文翻译：

---

艾沙妥昔单抗治疗复发/难治性多发性骨髓瘤

摘要

介绍

尽管新药类别显着延长了多发性骨髓瘤患者的生存期，但它们仍继续经历多次复发和/或变得难以治疗。因此，需要具有不同作用机制的新颖疗法和治疗组合以改善复发/难治性多发性骨髓瘤患者的预后。

覆盖区域

在这里，作者回顾了有关CD38单克隆抗体isatuximab的开发和临床研究的已发表数据，该药物用于治疗复发/难治性多发性骨髓瘤患者。总结了isatuximab治疗的作用机理，临床疗效和安全性。

专家意见

Isatuximab被批准与pomalidomide / dexamethasone联合用于治疗已接受至少两种先前疗法（包括来那度胺和蛋白酶体抑制剂）的复发/难治性多发性骨髓瘤患者。伊沙妥昔单抗显示出可控的安全性，其中输注反应是最常见的不良事件。目前正在对伊沙妥昔单抗与其他主治方案联合治疗复发/难治和新诊断的多发性骨髓瘤。